CTOs on the Move

Kedrion

www.kedrion.com

 
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.kedrion.com
  • 400 Kelby St Fl 11
    Fort Lee, NJ USA 07024
  • Phone: 201.242.8900

Executives

Name Title Contact Details

Similar Companies

Worldcare Limited

Worldcare Limited is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Awarepoint Corporation

Awarepoint Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Diego, CA. To find more information about Awarepoint Corporation, please visit www.awarepoint.com

Titanium Healthcare

Titanium Healthcare is one of the nation`s leading providers for specialty healthcare needs. Operating since October 2014 throughout 46 states, Titanium leads the way in compounded pharmaceuticals and nutraceuticals, injection kit solutions, pharmacogenetic testing and urine toxicology screening.

Patient Choice Healthcare Inc

Patient Choice Healthcare Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.